

Date: September 30, 2026

To, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001, India	To, National Stock Exchange of India Limited 'Exchange Plaza', C-1, Block-G, Bandra Kurla Complex, Bandra (East), Mumbai-400051, India	To, Bliss GVS Pharma Limited 102, Hyde Park, Sakivihar Road, Andheri (East), Mumbai- 400072, India
--	--	---

Dear Sir/Madam,

Subject: Disclosure under Regulation 29(1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 ("Takeover Regulations")

Ref.: Bliss GVS Pharma Limited (BSE Scrip Code: 506197, NSE Symbol: BLISSGVS)

Please find enclosed disclosure under Regulation 29(1) of the Takeover Regulations (*without PAN details*) in relation to the acquisition of equity shares of Bliss GVS Pharma Limited by Anupam Rasayan India Limited and Mates Visa Consultancy Private Limited.

We request you to kindly note the same and take into your records.

Thanking you,

Yours faithfully,

For and on behalf of Anupam Rasayan India Limited (Acquirer)

Anand
Sureshbhai Desai

Digitally signed by
Anand Sureshbhai Desai
Date: 2026.09.30
17:53:03 +05'30'

Anand Sureshbhai Desai
Managing Director
DIN: 00038442

For and on behalf of Mates Visa Consultancy Private Limited (PAC)

KALPESH
HEMANTBHAI
PANCHAL

Digitally signed by KALPESH
HEMANTBHAI PANCHAL
Date: 2026.09.30 16:34:10
+05'30'

Kalpesh Hemantbhai Panchal
Director
DIN: 10058215

Encl: As above

Disclosure under Regulation 29(1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A- Details of the Acquisition

Name of the Target Company ("TC")	Bliss GVS Pharma Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Anupam Rasayan India Limited ("Acquirer") and Mates Visa Consultancy Private Limited ("PAC")		
Whether the acquirer belongs to Promoter/Promoter group	Yes. Please refer to the Notes.		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited and the National Stock Exchange of India Limited		
Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	22,51,669^	2.12%^	2.07%^
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	0	0%	0%
c) Voting rights ("VR") otherwise than by equity shares	0	0%	0%
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	0	0%	0%
e) Total (a+b+c+d)	22,51,669^	2.12%^	2.07%^
Details of acquisition			
a) Shares carrying voting rights acquired	5,09,84,595#	47.95%#	46.77%#
b) VRs acquired otherwise than by equity shares	0	0%	0%
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	0	0%	0%
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	0	0%	0%

e) Total (a+b+c+d)	5,09,84,595#	47.95%#	46.77%#
After the acquisition, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	5,32,36,264^#	50.07%^#	48.84%^#
b) VRs otherwise than by equity shares	0	0%	0%
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	0	0%	0%
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	0	0%	0%
e) Total (a+b+c+d)	5,32,36,264^#	50.07%^#	48.84%^#
Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer/encumbrance, etc.)	Acquisition pursuant to the Share Purchase Agreement read with the Deed of Adherence (<i>as defined in the letter of offer dated 18 July 2026</i>). Please refer to the Notes.		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	Equity shares carrying voting rights.		
Date of acquisition of / date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.	28 September 2026 Please refer to the Notes for further details.		
Equity share capital / total voting capital of the TC before the said acquisition	10,60,56,222 equity shares of the TC (as per the shareholding pattern for the quarter ended 30 June 2026, as publicly disclosed by the TC on the websites of the stock exchanges). Subsequently, the TC disclosed increases to its total paid up equity share capital following allotments of equity shares to eligible employees who exercised their stock options under the Bliss GVS Pharma Limited-Employee Stock Option Plan 2019, as follows: (i) on 7 July 2026, to 10,62,43,972 equity shares; (ii) on 11 August 2026, to 10,62,75,222 equity shares; and (iii) on 4 September 2026, to 10,63,30,472 equity shares. Accordingly, in compliance with Regulation 29(1) of the SEBI (SAST) Regulations, the total share capital of the TC as disclosed by the TC on 4 September 2026 (i.e., 10,63,30,472 equity shares) has been considered for the purposes of calculation for this acquisition.		
Equity share capital/ total voting capital of the TC after the said acquisition	10,60,56,222 equity shares of the TC (as per the shareholding pattern for the quarter ended 30 June 2026, as publicly disclosed by the TC on the websites		

	of the stock exchanges). Subsequently, the TC disclosed increases to its total paid up equity share capital following allotments of equity shares to eligible employees who exercised their stock options under the Bliss GVS Pharma Limited-Employee Stock Option Plan 2019, as follows: (i) on 7 July 2026, to 10,62,43,972 equity shares; (ii) on 11 August 2026, to 10,62,75,222 equity shares; and (iii) on 4 September 2026, to 10,63,30,472 equity shares. Accordingly, in compliance with Regulation 29(1) of the SEBI (SAST) Regulations, the total share capital of the TC as disclosed by the TC on 4 September 2026 (i.e., 10,63,30,472 equity shares) has been considered for the purposes of calculation for this acquisition.
Total diluted share/voting capital of the TC after the said acquisition	10,86,91,222 equity shares of the TC (as per the shareholding pattern for the quarter ended 30 June 2026, as publicly disclosed by the TC on the websites of the stock exchanges) On 12 August 2026, the Nomination and Remuneration Committee of the TC granted 3,20,000 stock options under the Bliss GVS Pharma Limited-Employee Stock Options Plan 2019. Accordingly, in compliance with Regulation 29(1) of the SEBI (SAST) Regulations, the latest publicly available total diluted share capital of the TC as on 12 August 2026 (i.e., 10,90,11,222 equity shares) has been considered for the purposes of calculation for this acquisition

^The Acquirer acquired (i) 1669 equity shares of the TC, representing 0.00% of the paid-up equity share capital of the Target Company, pursuant to the completion of the Open Offer (as defined in the letter of offer dated 18 July 2026); and (ii) 22,50,000 equity shares of the TC, representing 2.12% of the paid-up equity share capital of the Target Company, pursuant to an on-market transaction. Collectively, the Acquirer holds 22,51,669 equity shares of the TC, representing 2.12% of the paid-up equity share capital of the Target Company.

The PAC has acquired 5,09,84,595 equity shares of the TC, representing 47.95% of the paid-up equity share capital of the TC, pursuant to the Share Purchase Agreement read with the Deed of Adherence (as defined in the letter of offer dated 18 July 2026).

Notes:

Capitalized terms used herein but not specifically defined shall have the same meaning ascribed to such terms in the letter of offer dated 18 July 2026 ("**Letter of Offer**"):

- (i) Upon the closure of the Tendering Period and the completion of payment of consideration, all 1,669 equity shares validly tendered by Public Shareholders in the Open Offer (representing 0.00% of the equity share capital of the TC) were credited to the demat account of the Acquirer on 24 August 2026.
- (ii) The Acquirer further acquired 22,50,000 equity shares of the TC (representing 2.12% of the equity share capital of the TC) pursuant to an on-market transaction on 28 September 2026.
- (iii) The Underlying Transaction, pursuant to which the Open Offer was made, was consummated on 28 September 2026. Upon the consummation of the Underlying Transaction, the PAC acquired 5,09,84,595 fully paid-up equity shares of the TC representing 47.95% of its equity share capital. For more information on the Underlying Transaction, please refer to paragraphs 7 to 9 of Part A (*Background to the Open Offer*) of Section III (*Details of the Open Offer*) of the Letter of Offer ([here](#)).
- (iv) Following the aforesaid acquisitions the Acquirer and the PAC collectively hold an aggregate of 5,32,36,264 equity shares of the TC, representing 50.07% of the equity share capital of the TC. Accordingly, with effect from 28 September 2026, pursuant to the completion of the Open Offer and the consummation of the Underlying Transaction, the Acquirer and the PAC have acquired control over the TC and have become promoters of the TC in accordance with the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement (i.e., presently the filing done under Regulation 31 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The total share capital of the TC of 10,63,30,472 fully paid-up equity shares, being the latest publicly available total equity share capital of the TC (i.e., as on 4 September 2026) has been relied upon for the purposes of calculation under this acquisition.

(**) Diluted share/ voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC. The total diluted share capital of the TC of 10,90,11,222 fully paid-up equity shares, being the latest publicly available total diluted equity share capital of the TC (i.e., as on 12 August 2026) has been relied upon for the purposes of calculation under this acquisition.

Signed for and on behalf of Anupam Rasayan India Limited (Acquirer)

Anand
Sureshbhai
Desai

Digitally signed by
Anand Sureshbhai Desai
Date: 2026.09.30
17:53:35 +05'30'

Name: Anand Sureshbhai Desai

Title: Managing Director

DIN: 00038442

Signed for and on behalf of Mates Visa Consultancy Private Limited (PAC)

**KALPESH
HEMANTBH
AI PANCHAL**

Digitally signed by
KALPESH
HEMANTBHAI
PANCHAL
Date: 2026.09.30
16:34:26 +05'30'

Name: Kalpesh Hemantbhai Panchal

Title: Director

DIN: 10058215